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Purpose: A possible involvement of autoimmune mecha-
nism in the pathogenesis of bronchial asthma has been
proposed. Recently, alpha-enolase protein was identified as a
major autoantigen recognized by circulating IgG autoanti-
bodies in patients with severe asthma. To evaluate a possible
pathogenetic significance of these autoantibodies in severe
asthma, isotype (IgG, IgA, IgM, and IgE) and IgG subclass
(IgG1, IgG2, IgG3, and IgG4) distributions of autoantibodies
to recombinant human alpha-enolase protein were analyzed.
Patients and Methods: We examined serum samples from 10
patients with severe asthma and 7 patients with mild-to-mod-
erate asthma, and 5 healthy controls by immunoblot analysis.
Severe asthma was defined as patients having at least 1 se-
vere asthmatic exacerbation requiring an emergency depart-
ment visit or admission in the last year despite continuous
typical therapies. Results: IgG1 was the predominant IgG
subclass antibody response to alpha-enolase protein in pa-
tients with severe asthma. IgG1 autoantibody to alpha-enolase
protein was detected in 7 of 10 patients with severe asthma
(70%), 1 of 7 patients with mild-to-moderate asthma (14.3%),
and none of 5 healthy controls (0%) (chi-square test; p <
0.05). IgA, IgM, and IgE autoantibodies to alpha-enolase pro-
tein could not be detected in patients with severe asthma.
Conclusion: IgG1 subclass was the predominant type of auto-
antibody response to alpha-enolase protein in patients with
severe asthma, suggests a possibility of IgG1 autoantibody-
mediated complement activation in the pathogenesis of severe
asthma.
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INTRODUCTION
Asthma is a chronic inflammatory airway disease
that can be severe and sometimes fatal.
1 It has been
estimated that 5 to 10 percent of patients with
asthma have severe disease that is not effectively
controlled by typical therapies, and these patients
are at high risk of asthma-related death.
1,2 Severe
asthma has several distinct characteristics com-
pared to mild-to-moderate asthma, such as female
dominance, less allergic sensitization, and history
of more frequent aspirin-hypersensitivity.
2 How-
ever, there is still little information on the patho-
physiological mechanism responsible for severe
asthma.
1-3
It has repeatedly been suggested that autoimmu-
ne mechanism might be involved in the pathogene-
sis of asthma.
4-6 The autoimmune hypothesis of
asthma is based on the presence of autoantibodies
to the target tissue of inflammation (lung and
bronchial mucosa),
6-8 common genetic association,
frequent coexistence with autoimmune diseases,
9,10
and response to medications used for systemic
autoimmune diseases such as systemic cortico-
steroid and anti-TNF reagents.
11,12 However, a
pathogenic role of autoimmune response in the
pathogenesis of asthma has not yet been demon-
strated.
Interestingly, IgG autoantibody to a 55-kDa
protein in endothelial cells and platelets has been
reported to be associated with severe asthma.
8
Recently, alpha-enolase protein has been identified
as a common autoantigen of endothelial cells,
bronchial epithelial cells, and platelets, recognized
by circulating IgG autoantibodies in patients with
severe asthma.
13 It has been suggested that alpha-
enolase could be the same antigen that has been
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previously reported as a 55-kDa endothelial auto-
antigen.
8,13
IgM autoantibodies to alpha-enolase have been
detected in patients with Behçet's disease
14 and
IgE autoantibodies to unidentified 55-kDa endo-
thelial cell antigen have previously been detected
in patients with severe asthma.
8 We hypothesized,
therefore, that a preference of specific immuno-
globulin isotype of autoantibody response to
alpha-enolase protein might be related with dif-
ferent clinical manifestations in the specific
diseases with autoimmune response to alpha-
enolase protein.
In this study, we analyzed isotype and IgG
subclass distributions of autoantibodies response
to alpha-enolase protein in serum samples from
adult patients with severe asthma and evaluated
possible pathogenetic significance of the auto-
antibody in severe asthma, especially a possibility
of IgE-mediated autoallergic reaction or IgG auto-
antibody-mediated complement activation.
PATIENTS AND METHODS
Subjects
We used serum samples from 10 patients with
severe asthma and 7 patients with mild-to-
moderate asthma, and 5 healthy controls (Table 1).
All patients had typical clinical history of asthma
and documented reversibility of FEV1 greater than
12% after inhalation of bronchodilator. All patients
with severe asthma had typical clinically charac-
teristics of difficult-to-control by standard medical
treatments and required frequent administrations
of oral corticosteroids for control of their asthma.
They had clinical history of at least 1 severe
asthmatic exacerbation requiring an emergency
department visit or admission in the last year
despite continuous typical therapies as defined
previously.
13 All patients underwent skin-prick
test with 50 common aeroallergens (Bencard Co.,
Brentford, UK). Atopy was defined when there
was a positive skin reaction to any one of the 50
common aeroallergens.
13 All subjects gave written
informed consent and the institutional review
board approved this study.
Production and purification of recombinant
human alpha-enolase protein
Recombinant human alpha-enolase protein was
produced using Escherischia coli BL21 cells and
purified as previously described.
14
Immunoblot analysis of IgG, IgA, and IgM auto-
antibodies to alpha-enolase
Recombinant human alpha-enolase protein was
separated by a discontinuous sodium dodecyl
sulfate/polyacrylamide gel electrophoresis (SDS-P
AGE) as previously described.
13 Following elec-
trophoresis, protein in the gel was transferred
onto a polyvinylidene difluoride membrane (PVDF;
Bio-Rad Laboratories, Hercules, CA, USA). After
the transfer, the membrane was incubated for 1
hour with Tris-buffered saline (TBS) containing
0.1% Tween 20, 10% Skim milk, and 10% bovine
serum. The membrane strips were incubated for
2 hours with 1 mL of serum samples at a dilution
of 1 in 100 (v/v) at room temperature. After
washes, the membrane was incubated for 2 hours
with alkaline phosphatase-conjugated goat anti-
human IgG, anti-human IgA, or anti-human IgM
(Sigma Chemical Co., St. Louis, MO, USA) at room
temperature. After a final washing, the membrane
was stained with a substrate solution (nitro blue
tetrazolium/5-bromo-4-chloro-3-indoyl phosphate;
Sigma Chemical Co., St. Louis, MO, USA). Goat
specific antibody to human alpha-enolase protein
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)
was used as a positive control and detected by
alkaline phosphatase-conjugated anti-goat anti-
body. Autoantibody was defined as positively
detected if a stained density of immunoblot of the
serum sample was definitely visible and com-
parable to density produced by a goat specific
antibody to human alpha-enolase.
Immunoblot analysis of IgG subclass autoantibodies
to alpha-enolase
For the detection of IgG subclass autoantibodies
to alpha-enolase protein, PVDF membrane strips
described above were incubated with various
dilutions of serum samples (IgG1, 1 : 100 ; IgG2, 1:
100 ; IgG3, 1 : 10, and IgG4, 1 : 10 dilution) and inAutoantibody to Alpha-enolase Protein in Asthma
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cubated for 3 hours at room temperature. After
washes, monoclonal anti-human IgG subclass
antibodies (clone 8c/6-39 for IgG1, HP-6002 for
IgG2, HP-6050 for IgG3, HP-6023 for IgG4; Sigma
Chemical Co., St. Louis, MO, USA) were diluted
at 1 : 1000 and incubated for 2 hours at room
temperature. After washes, the membrane was
incubated with alkaline phosphatase-conjugated
goat anti-mouse IgG (Sigma Chemical Co., St.
Louis, MO, USA) for 2 hours at room temperature.
After a final washing, the PVDF strips were stained
as described above.
Immunoblot analysis of IgE autoantibody to alpha-
enolase
Immunoblot analysis of IgE autoantibody to
alpha-enolase was carried out according to the
method used for the detection of specific IgE
antibody to house dust mite allergen.
15 The PVDF
Table 1. Characteristics of Study Subjects and Detection of IgG Subclass Autoantibodies to Alph-enolase Protein
Group
Subject
No.
Sex
Age
(yrs)
Atopy
FEV1
(%)
Immunoblot detection of
autoantibodies to alpha-enolase
IgG IgG1 IgG2 IgG3 IgG4
Healthy controls 1 F 32 N.D. 92 - - - - -
2 F 39 N.D. 104 - - - - -
3 F 44 N.D. 129 - - - - -
4 F 41 N.D. 119 - - + - -
5 F 35 N.D. 125 - - - - -
Mild-to-moderate
asthma
6 M 20 + 76 - - - - -
7 M 22 + 88 - - - - -
8 F 24 + 64 - - - - -
9 M 19 + 73 - - - - -
10 M 27 + 93 + + - - -
11 M 19 + 28 - - - - -
12 F 22 + 97 - - - + -
Severe asthma 13 F 58 - 47 - - - - -
14 F 71 - 88 - - - - -
15 F 64 - 85 - - - - -
16 M 34 + 42 + + - - -
17 F 51 - 81 + + - - -
18 M 20 - 57 + + - - -
19 F 46 - 67 + + + + +
20 F 47 - 81 + + + - -
21 F 46 + 73 + + - + +
22 F 64 - 77 + + - - -
F, female; M, male; N.D., not determined.Hye-Ah Lee, et al.
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membrane strips described above which contained
recombinant human alpha-enolase protein were
incubated for 3 hours with dilution of serum
samples (1 : 10 dilution) at room temperature. After
three washes, the membrane was incubated for 2
hours with affinity-purified and biotinylated anti-
IgE (Vector Laboratories Inc., Burlingame, CA,
USA) at room temperature. After washing, the
membrane was incubated for 1 hour with alkaline
phosphatase conjugated streptavidin (Sigma Che-
mical Co., St. Louis, MO, USA) at room tempera-
ture. After washing, the PVDF strips were stained
as described above.
Statistics
The chi-square test was used to compare the
gender ratio, atopy, and the detection rate of
autoantibodies between groups. A p value < 0.05
was regarded as statistically significant when com-
paring the two groups.
RESULTS
Isotype distribution of autoantibody to alpha-
enolase protein
IgG autoantibody to alpha-enolase protein was
detected in serum samples from 7 of 10 patients
with severe asthma (70%), 1 of 7 patients with
mild-to-moderate asthma (14.3%), and 0 of 5
healthy controls (0%) (chi-square test, p < 0.05)
(Fig. 1 and Table 1). On the other hand, IgA, IgM,
Fig. 1. Immunoblot analysis of circulating autoantibodies to recombinant human alpha-enolase protein; isotype distribution
of IgG (A), IgA (B), IgM (C), and IgE autoantibodies (D). Results from healthy controls (CON, lane 1 - 5), patients with
mild-to-moderate asthma (MMA, lane 6 - 12), and patients with severe asthma (SA, lane 13 - 22), and specific antibody to
alpha-enolase as a positive control (P, lane 23). *Arrow indicates alpha-enolase protein.
A B
C DAutoantibody to Alpha-enolase Protein in Asthma
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and IgE autoantibodies to alpha-enolase protein
could not be detected in all patients with severe
asthma on mild-to-moderate asthma, and healthy
controls (Fig. 1).
IgG subclass distribution of IgG autoantibody to
alpha-enolase protein
IgG1 autoantibody to alpha-enolase protein was
detected in 7 of 10 patients with severe asthma
(70%), 1 of 7 patients with mild-to-moderate as-
thma (14.3%), and none of 5 healthy controls (0%)
(chi-square test; p < 0.05) (Fig. 2 and Table 1). IgG2,
IgG3, and IgG4 autoantibodies to alpha-enolase
protein were detected only in 2 of 10 patients with
severe asthma (20%) (Table 1). There were no
significant differences in the detection rates of
IgG2, IgG3, and IgG4 subclass autoantibodies to
alpha-enolase protein among patients with severe
asthma on mild-to-moderate asthma, and healthy
controls (p > 0.05) (Fig. 2 and Table 1).
The pattern of immunoblot detection of IgG1
autoantibody to alpha-enolase in all subjects tested
was exactly similar to the pattern of IgG auto-
antibody to alpha-enolase (Figs. 1 and 2). Con-
sequently, the IgG1 subclass was the predominant
type of autoantibody response to alpha-enolase
protein in patients with severe asthma.
DISCUSSION
In this study, we found that IgG antibody was
a dominant isotype among the IgG, IgA, IgM, and
IgE autoantibody responses to alpha-enolase
protein in patients with severe asthma. We also
Fig. 2. Immunoblot analysis of IgG subclass autoantibodies to recombinant human alpha-enolase protein; IgG1 (A), IgG2
(B), IgG3 (C), and IgG4 autoantibodies (D) analysis. Results from healthy controls (CON, lane 1 - 5), patients with
mild-to-moderate asthma (MMA, lane 6 - 12), and patients with severe asthma (SA, lane 13 - 22), and specific antibody to
alpha-enolase as a positive control (P, lane 23). *Arrow indicates alpha-enolase protein.
A B
D CHye-Ah Lee, et al.
Yonsei Med J Vol. 49, No. 6, 2008
found that IgG1 subclass was the predominant
type of IgG subclass autoantibody response to
alpha-enolase protein in patients with severe
asthma. This finding suggests a possible involve-
ment of IgG1 autoantibody-mediated complement
activation in the pathogenesis of severe asthma.
A possible involvement of autoimmune mecha-
nism in the pathogenesis of bronchial asthma has
been suggested for a long time (at least more than
40 years).
6-8 Previous studies have shown the pre-
sence of circulating autoantibodies to the bronchial
mucosa tissue, lung tissue, endothelial cells, and
epithelial cells in patients with bronchial asthma.
4,6-8
The beta-2 adrenergic receptor, vasoactive intesti-
nal peptide, cytokeratin 18 protein, and alpha-
enolse protein were identified as autoantigens
associated with bronchial asthma.
4,7,13,16 Unfor-
tunately, however, autoantibody responses to the
above identified autoantigens are not specific to
bronchial asthma, and detected in many other
chronic inflammatory diseases including systemic
vasculitis, inflammatory bowel diseases, endo-
metriosis, autoimmune hepatitis, and rheumatoid
arthritis.
7,13,16,17 These findings suggest that autoim-
mune responses observed in the bronchial asthma
could be an epiphenomenon which reflects damage
of bronchial tissue, resulting from chronic airway
inflammation. However, a possibility of patho-
genic contribution of autoantibody response by
inducing airway inflammation could not be
excluded either.
There are several reports on in vitro experiment
to study the functional significance of the autoim-
mune response observed in patients with bronchial
asthma.
4 One important characteristic of circu-
lating autoantibodies in patients with bronchial
asthma was that the autoantibodies were comple-
ment-fixing antibodies.
18 The presence of antinu-
clear antibody was significantly associated with
elevated serum levels of activated complement in
patients with bronchial asthma.
19 Circulating
concentration of activated complement was also
significantly increased in patients with aspirin-
sensitive asthma compared to aspirin-tolerant
asthma and healthy controls.
20 Theoretically, com-
plement fixing autoantibodies to antigens which
exist in the bronchial mucosa tissue can activate
the complement system, thereby inducing bron-
chial smooth muscle contraction and mucosal
inflammation by generating anaphylactoxin (C3a
and C5a).
21 A possible involvement of autoanti-
body-mediated complement activation in the
pathogenesis of bronchial asthma can further be
supported by the deposition of immunoglobulin
and complement and up-regulation of complement
receptors on the epithelial cells and endothelial
cells in the bronchial mucosa tissue from asthmatic
patients who died of severe asthmatic attack.
22,23
However, the pathogenetic significance of autoim-
mune response observed in patients with bronchial
asthma should further be tested by establishing an
animal model of "autoimmune asthma".
Circulating IgE autoantibody to 55-kDa autoan-
tigen which is commonly expressed in endothelial
cells and platelets has previously been detected in
2 among 97 patients with bronchial asthma.
8 We
have recently identified that an alpha-enolase
protein is the autoantigen recognized by circulating
autoantibodies from patients with severe asthma
and commonly expressed in the endothelial cells,
airway epithelial cells, and platelets.
13 We also sug-
gested that previously reported 55-kDa endothelial
autoantigen could be an alpha-enolase protein.
13 In
the present study, therefore, we tested a possible
existence of IgE autoantibody to human alpha-
enolase proteins in the serum samples from
patients with severe asthma, however, we could
not detect IgE autoantibody in serum samples
from 10 patients with severe asthma including 7
patients with severe asthma who had a circulating
IgG autoantibody to alpha-enolase protein, sug-
gesting a low possibility of IgE autoantibody-
mediated activation of mast cells in these patients
with severe asthma. The predominance of IgG1
subclass autoantibody response to alpha-enolase
protein observed in patients with severe asthma is
also compatible with previous studies which
analyzed the IgG subclass distribution of autoanti-
body response to alpha-enolase protein in patients
with primary membranous nephropathy.
24 Al-
though IgM autoantibodies to alpha-enolase were
detected in patients with Behçet's disease,
14 we
could not detect IgM autoantibodies to alpha-
enolase in patients with severe asthma. These
results suggest that a preference of specific im-
munoglobulin isotype in autoantibody response to
alpha-enolase protein might be associated with
different clinical manifestations in the specificAutoantibody to Alpha-enolase Protein in Asthma
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diseases which have autoimmune response to
alpha-enolase protein.
The IgG subclass antibody response was sug-
gested to be regulated by balance of Th1 and Th2
cell response to the antigen.
25,26 Generally, IgG1
antibody response has been suggested to be sti-
mulated by the Th1 cells response to the antigen.
25,26
Therefore, the predominance of IgG1 subclass
autoantibody to alpha-enolase protein in patients
with severe asthma suggests that activation of Th1
cells is specific to alpha-enolase protein in patients
with severe asthma. The above hypothesis is
compatible with previous studies on T cells and
cytokines in blood samples and bronchial mucosa
tissues of patients with severe asthma.
5
In conclusion, IgG1 subclass was the predo-
minant type of autoantibody response to alpha-
enolase protein in patients with severe asthma and
this finding suggests a possible involvement of
IgG1 autoantibody-mediated complement activa-
tion in the pathogenesis of severe asthma. However,
further studies are needed to determine the func-
tional significance of IgG1 autoantibody response
to alpha-enolase protein observed in patients with
severe asthma.
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